Rob Hart

Rob Hart has an extensive work history in the biotechnology and pharmaceutical industries. Rob began their career in 2007 as a Partner with Telegraph Hill Partners. In 2010, they joined MedPricer.com as a Director, where they played a role in the acquisition of the company by Premier, Inc. In 2015, Rob became a Co-Founding Investor, Former CFO, and Director of Akoya Biosciences, Inc., a company specializing in spatial biology and high parameter tissue analysis, which later went public in 2021.

Rob's other roles include Director positions at TrakCel Ltd., Aquaro Biosystems, and Verogen. Rob also served as a Secretary and Board Observer at Specific Diagnostics, a company acquired by bioMérieux S.A., specializing in rapid antibiotic susceptibility testing. Additionally, Rob has held Director positions at Nivagen Pharmaceuticals, Inc., Nimble Therapeutics, and Invisalert Solutions, Inc.

Overall, Rob's work experience showcases their expertise and involvement in various aspects of the biotechnology and pharmaceutical industries, including investments, strategic leadership, and company acquisitions.

Rob Hart has a diverse education background. Rob obtained a Master of Business Administration (M.B.A.) degree from Northwestern University - Kellogg School of Management in 2004. In the same year, they also earned a Doctor of Law (J.D.) degree from Northwestern University Pritzker School of Law. Prior to this, they completed their undergraduate studies at UC Santa Barbara, where they obtained both a Bachelor of Science (B.S.) and a Bachelor of Arts (B.A.) degree in Geology and Economics. Rob Hart attended Mira Loma High School, a public school, but no specific degree is mentioned. Additionally, they hold a Chartered Financial Analyst certification from the CFA Institute, which they obtained in January 2001.